Quick Take
Recro Pharma (NASDAQ:REPH) has priced its offering to sell approximately $39 million of new common stock.
The company is developing promising pain treatments and is nearing the end of Phase III trials for its lead candidate Meloxicam.
Recro also operates a contract manufacturing facility, which appears to positively contribute to the company's financials.
My recommendation is to wait until full year 2016 financial results are published, and management releases its 2017 forward guidance.
